Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. The California-based pharma ...
Gilead Sciences' cell therapy Kite Pharma has bulked up its position in ... said the deal will "potentially accelerate Shoreline's timeline to the clinic, expand our pipeline opportunities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback